Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023 76

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023 76

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Updated on: October 24,2023 4

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Updated on:October 24,2023 4

Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma

August 27, 2022Lisa AstorRelapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.Multiple Mye

Updated on: October 24,2023 31

Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma

August 27, 2022Lisa AstorRelapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.Multiple Mye

Updated on:October 24,2023 31

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25, 2022Lindsay FischerPatients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.Effective methods of m

Updated on: October 24,2023 18

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25, 2022Lindsay FischerPatients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.Effective methods of m

Updated on:October 24,2023 18

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

September 9, 2021Darlene Dobkowski, MAFor patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease m

Updated on: October 24,2023 6

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

September 9, 2021Darlene Dobkowski, MAFor patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease m

Updated on:October 24,2023 6

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21, 2023Gina MauroSelpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients

Updated on: October 24,2023 2

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21, 2023Gina MauroSelpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients

Updated on:October 24,2023 2

After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23, 2023Dylann Cohn-EmeryContinued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit v

Updated on: October 24,2023 4

After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23, 2023Dylann Cohn-EmeryContinued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit v

Updated on:October 24,2023 4

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26, 2023Pankit Vachhani, MDPrithviraj Bose, MDThe hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tr

Updated on: October 24,2023 23

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26, 2023Pankit Vachhani, MDPrithviraj Bose, MDThe hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tr

Updated on:October 24,2023 23

Scalp Cooling for Chemo Hair Loss Strikes Out With Patients

M. Alexander Otto, PA, MMSTOPLINE:Most women withbreast cancerwho received scalp cooling did not perceive benefits in preventing hair loss, overall quality of life, body image, and other o

Updated on: October 26,2023 37

Scalp Cooling for Chemo Hair Loss Strikes Out With Patients

M. Alexander Otto, PA, MMSTOPLINE:Most women withbreast cancerwho received scalp cooling did not perceive benefits in preventing hair loss, overall quality of life, body image, and other o

Updated on:October 26,2023 37

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell

Updated on: October 27,2023 25

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell

Updated on:October 27,2023 25

SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers

Damian McNamara, MAVANCOUVER, Canada — Use of sodium glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancers among patients withtype 2 diabe

Updated on: October 27,2023 23

SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers

Damian McNamara, MAVANCOUVER, Canada — Use of sodium glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancers among patients withtype 2 diabe

Updated on:October 27,2023 23

Using the immune system to fight cancer: an interview with Dr Charles Akle

Why does cancer occur?We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system.However, if someth

Updated on: October 27,2023 9

Using the immune system to fight cancer: an interview with Dr Charles Akle

Why does cancer occur?We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system.However, if someth

Updated on:October 27,2023 9